Mayo Clinic researchers have developed a process that uses human cells as inks, dubbed bioinks, to print natural tissue-like structures in three dimensions.
Could 3D technology lead to a new treatment for inflammatory skin disease? Mayo Clinic researchers believe the answer is yes. They’ve developed a 3D prototype they describe as “the most human-like skin model” for studying atopic dermatitis and other skin conditions.
The 3D technology brings new options, says Saranya Wyles, M.D., Ph.D., a dermatologist, in a Mayo Clinic press release. “It can create human equivalents that are truer and more representative of the disease, unlike the animal models we have worked with in the past. Inflammatory skin diseases and rare diseases can be modeled for better understanding of the underlying pathology and drug testing and how that might affect the patient."
The process they’re using is bioprinting, which uses human cells as inks, called bioinks, to print natural tissue-like structures in three dimensions. The bioinks act much like ink from a printer ink cartridge.
“We can print the skin from cells of patients with atopic dermatitis or eczema," says Wyles, who is the senior author of a report about the prototype in Regenerative Biomaterials. "Our system allows us to use up to six different cell types to model and recreate human skin tissue."
The printing process is “sort of like creating layers of a tiered cake with different cell types," Wyles adds. "You start at the bottom (the dermis), then you add the next layer (the epidermis), and the scaffold material acts as the frosting to connect the layers. The printed skin is put into an incubator where the cells can communicate with each other, expand and form bioprinted skin."
However, the researchers have their job cut out for them. Three-dimensional bioprinting uses biomaterials, cells and culturing techniques to create “biologically equivalent models with key features to replicate the phenotype and function of the desired organ.” That means incorporating many types of cells, including melanocytes (which form skin pigment), keratinocytes (which allow for skin renewal), and fibroblasts (which form a connective tissue). The cells are printed in layers that stratify and mature into full layers of skin. The 3D bioprinting model will need to replicate that complexity, but has yet to incorporate the sweat glands, blood vessels, skin follicles and nerves found in native human tissue, the researchers say. Also, the biomaterial needs specific characteristics: For instance, in the case of grafts for blistering skin conditions, the biomaterial should have strong water-biomaterial interactions that modulate cell adhesion—without that, the bioink may not be compatible with the grafted site and will be rejected.
The technology has the potential to transform clinical and laboratory practice, Wyles says. "This 3D model more accurately recreates disease, creates surgical grafts and provides the ability to test new therapies." More research is needed, though, to bioprint an exact replica of “patient-specific” human skin with atopic dermatitis.
Joseph Zabinski Advocates for Patient Trust in AI Adoption in Dermatology Care
April 18th 2024Joseph Zabinski, PhD, MEM, vice president, head of commercial strategy and AI, OM1, chatted with MHE editors on the significance of patient acceptance in AI adoption in healthcare, overall and in the dermatology space, stressing trust and transparency.
Read More
Microneedling Combined with Other Vitiligo Therapies Offers Promising Treatment for Skin Disease
April 10th 2024Researchers of a study conducted a double-blind intervention that aimed to assess the effectiveness and tolerance of a new approach for vitiligo treatment using meso-microneedling with 5% N-acetylcysteine (NAC) ampoules and topical 4.7% NAC, compared to microneedling alone.
Read More
Positive Results for Ruxolitinib Cream in Children with Atopic Dermatitis Presented in Ongoing Study
March 18th 2024Ruxolitinib cream showed positive results in children 2- to 11-years-old with mild to moderate atopic dermatitis (AD), according to data of a poster presented at the American Academy of Dermatology Annual Meeting in San Diego from March 8 to 12.
Read More
Opzelura Provides Benefit in Atopic Dermatitis in Real-World Studies | AAD 2024
March 8th 2024Physicians switch to Opzelura (ruxolitinib) when other therapies fail to help patients with atopic dermatitis, according to a new analysis presented at the annual meeting of the American Academy of Dermatology.
Read More